反相色谱 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Studies in bird behaviour include the use of tamed and trained birds in captivity. Studies on bird intelligence and song learning have been largely laboratory-based. Field researchers may make use of a wide range of techniques such as the use of dummy owls to elicit mobbing behaviour, and dummy males or the use of call playback to elicit territorial behaviour and thereby to establish the boundaries of bird territories. Studies of bird migration including aspects of navigation, orientation, and physiology are often studied using captive birds in special cages that record their activities. The Emlen funnel, for instance, makes use of a cage with an inkpad at the centre and a conical floor where the ink marks can be counted to identify the direction in which the bird attempts to fly. The funnel can have a transparent top and visible cues such as the direction of sunlight may be controlled using mirrors or the positions of the stars simulated in a planetarium. The entire genome of the domestic fowl (Gallus gallus) was sequenced in 2004, and was followed in 2008 by the genome of the zebra finch (Taeniopygia guttata). Such whole-genome sequencing projects allow for studies on evolutionary processes involved in speciation. Associations between the expression of genes and behaviour may be studied using candidate genes. Variations in the exploratory behaviour of great tits (Parus major) have been found to be linked with a gene orthologous to the human gene DRD4 (Dopamine receptor D4) which is known to be associated with novelty-seeking behaviour.
The type of fats in the diet is also important, with saturated fat and trans fats increasing the risk and polyunsaturated and monounsaturated fat decreasing the risk. Eating white rice excessively may increase the risk of diabetes, especially in Chinese and Japanese people. Adverse childhood experiences, including abuse, neglect, and household difficulties, increase the likelihood of type 2 diabetes later in life by 32%, with neglect having the strongest effect. Antipsychotic medication, SSRI, and SNRI side effects (specifically metabolic abnormalities, dyslipidemia and weight gain) are also potential risk factors.
=== Contestants === 1st - Renee Loranger, Pastry Chef from Waveland, Mississippi 2nd - Guillermo Salinas from Jackson, Mississippi 2nd - Adina Schaefer, Executive Pastry Chef from Los Angeles, California 4th - Megan Baker, Bakery Owner from Minneapolis, Minnesota 5th - Ashley Wong from Fremont, California 6th - Wes Dills from Austin, Texas 7th - Sherelle Morrison from Indian Land, South Carolina 8th - Jocelyn Jung, Bakery Owner from San Diego, California 9th - Anirudh Mamtora from Cherry Hill, New Jersey 9th - Nicole Proske from Miami, Florida 11th - Steven Sechoka from Boston, Massachusetts 12th - Paul Allicock from Miami, Florida
=== Equity === Digital agriculture shows promise for creating a more equitable agri-food value chain. Because digital technologies reduce transaction costs and information asymmetries, they can improve smallholder farmers' market access in a number of ways:
Railway transport in Malaysia is state-run, and spans some 2,783 kilometres (1,729 mi). As of 2016, Malaysia has the world's 26th-largest road network, with some 238,823 kilometres (148,398 mi) of roads. Malaysia's inland waterways are the world's 22nd-longest, and total 7,200 km (4,474 mi). Among Malaysia's 114 airports, the busiest one is Kuala Lumpur International Airport (KLIA), located in the Sepang District; it is also the 12th-busiest airport in Asia. Among the seven federal ports, the major one is Port Klang, which is the 13th-busiest container port. Malaysia's flag carrier is Malaysia Airlines, providing international and domestic air services. Malaysia's telecommunications network is second only to Singapore's in Southeast Asia, with 4.7 million fixed-line subscribers and more than 30 million cellular subscribers. There are 200 industrial parks along with specialised parks such as Technology Park Malaysia and Kulim Hi-Tech Park. Fresh water is available to over 95% of the population, with groundwater accounting for 90% of the freshwater resources. Although rural areas have been the focus of great development, they still lag behind areas such as the West Coast of Peninsular Malaysia. The telecommunication network, although strong in urban areas, is less available to the rural population. Malaysia's energy infrastructure sector is largely dominated by Tenaga Nasional, the largest electric utility company in Southeast Asia. Customers in Peninsular Malaysia are connected to electricity through the National Grid.
Sources: en.wikipedia.org
=== Activism === Throughout her life, Kidder was active in environmental and anti-nuclear causes. On August 23, 2011, Kidder, Tantoo Cardinal, and dozens of others were arrested while protesting in Washington, DC, against the proposed extension of the Keystone Pipeline. In 2012, she appeared in a video for Stop the Frack Attack, an environmental organization working toward regulating hydraulic fracturing ("fracking") practices. When discussing sustainable energy, Kidder said: "The first thing people have to start facing, contrary to the advertising fed to us by oil and gas companies, is that environmentalism and economic stability go hand-in-hand on any long-term basis." Kidder spent the winter of 2016–2017 residing in a tent at the Standing Rock Reservation in North Dakota, protesting the Dakota Access Pipeline. In addition to environmental causes, Kidder was a vocal supporter of LGBTQ rights, and in 2003, hosted benefits at a gay and lesbian health center in Boston, Massachusetts. Following her publicized nervous breakdown in 1996, she also spoke outwardly about her struggles with mental health and her bipolar disorder diagnosis. In 2001, she was awarded the Courage in Mental Health Award from the California Women's Mental Health Policy Council for her public dialogue on mental illness.
== Connective tissue-activating peptide III == Connective tissue-activating peptide III (CTAP-III), also called Low-affinity platelet factor IV (LA-PF4), is a protein that corresponds to positions 44-128 of PPBP. This protein has mitogenic effects: stimulating DNA synthesis and mitosis. It also triggers prostaglandin E2 secretion and synthesis of hyaluronic acid and sulfated glycosaminoglycan.
Technetium-99m's short half-life of 6 hours makes long-term storage impossible. Transport of 99mTc from the limited number of production sites to radio pharmacies (for manufacture of specific radiopharmaceuticals) and other end users would be complicated by the need to significantly overproduce to have sufficient remaining activity after long journeys. Instead, the longer-lived parent nuclide 99Mo can be supplied to radio pharmacies in a generator, after its extraction from the neutron-irradiated uranium targets and its purification in dedicated processing facilities. Radio pharmacies may be hospital-based or stand-alone facilities, and in many cases will subsequently distribute 99mTc radiopharmaceuticals to regional nuclear medicine departments. Development in direct production of 99mTc, without first producing the parent 99Mo, precludes the use of generators; however, this is uncommon and relies on suitable production facilities close to radio pharmacies.
Rongliflozin/Olorigliflozin has been evaluated in phase I trials, but is not yet approved by the FDA Sergliflozin etabonate discontinued after phase II trials. Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Tofogliflozin, developed by Sanofi and Kowa Pharmaceutical, was approved in Japan in March 2014, under the brand names Apleway and Deberza. Velagliflozin, marketed as Senvelgo, produced by Boehringer Ingelheim Animal Health, was approved for use in diabetic cats in 2023.
"Adequate calcium throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis." "Adequate calcium as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life." "Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis." "Adequate calcium and vitamin D as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life." In the same year, the European Food Safety Authority also approved a dietary supplement health claim for calcium and vitamin D and the reduction of the risk of osteoporotic fractures by reducing bone loss. The U.S. FDA also approved Qualified Health Claims (QHCs) for various health conditions for calcium, selenium and chromium picolinate. QHCs are supported by scientific evidence, but do not meet the more rigorous "significant scientific agreement" standard required for an authorized health claim. If dietary supplement companies choose to make such a claim then the FDA stipulates the exact wording of the QHC to be used on labels and in marketing materials. The wording can be onerous: "One study suggests that selenium intake may reduce the risk of bladder cancer in women. However, one smaller study showed no reduction in risk.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.